Diabetic Gastroparesis Market to Reach $5.46B by 2030 at 6.3% CAGR
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Diabetic Gastroparesis Treatment Market Expected To Scale Between 2026 And 2030?
The diabetic gastroparesis treatment market has shown significant growth in recent years. Its size is expected to expand from $4.05 billion in 2025 to $4.28 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.7%. This historical period’s expansion is linked to factors such as rising diabetes complications, limited historical treatment options, increasing diagnosis rates, reliance on pharmacological management, and growth in gastroenterology specialty care.
The diabetic gastroparesis treatment market size is projected to experience substantial expansion in the coming years. It is anticipated to reach $5.47 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.3%. This growth during the forecast period can be primarily attributed to the emergence of novel prokinetic agents, heightened disease awareness, the proliferation of specialized clinics, a growing demand for sustained symptom control, and innovations in gastric stimulation technologies. Major trends over the projected timeframe include a rising utilization of prokinetic drug therapies, an increasing emphasis on symptom-focused disease management, an broadening of combination pharmacological treatments, a growing adoption of minimally invasive interventions, and a greater focus on dietary and lifestyle modifications.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Major Drivers Are Influencing The Expansion Of The Diabetic Gastroparesis Treatment Market?
The rising incidence of diabetes is anticipated to fuel the expansion of the Diabetic Gastroparesis Treatment Market in the future. Diabetes prevalence signifies the portion or percentage of individuals within a population identified with diabetes at a particular moment. Treatments for diabetic gastroparesis primarily focus on alleviating the symptoms and related complications of this condition, which is frequently associated with diabetes. For example, data from April 2025 provided by the International Diabetes Federation, a Belgium-based international not-for-profit federation of national diabetes associations, indicated that approximately 589 million adults between the ages of 20 and 79 globally had diabetes, with this figure expected to increase to 853 million by 2050. Consequently, the growing prevalence of diabetes is a significant factor driving the Diabetic Gastroparesis Treatment Market.
What Segment Categories Shape The Diabetic Gastroparesis Treatment Market Segment Landscape?
The diabetic gastroparesis treatment market covered in this report is segmented –
1) By Treatment: Medication, Surgery
2) By Route Of Administration: Oral, Injectables
3) By Indication: Compensated Gastroparesis, Gastric Failure
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Medication: Prokinetic Agents, Antiemetics, Antidepressants
2) By Surgery: Gastric Electrical Stimulation, Surgical Procedures For Gastric Drainage
Which Trends Are Shaping The Diabetic Gastroparesis Treatment Market?
Major companies operating in the diabetic gastroparesis treatment market are developing advanced solutions, including small bowel intubation, to enhance the precision of diagnoses and the effectiveness of treatments. Small bowel intubation entails placing a tube into the small intestine, enabling more exact monitoring and therapeutic interventions for conditions such as diabetic gastroparesis, where gastric motility is compromised. For instance, in September 2024, Avenacy, a US-based pharmaceutical company, launched Metoclopramide Injection (USP) in the Unites States. Metoclopramide Injection (USP) is an injectable medication designed for several indications, notably providing relief for symptoms associated with diabetic gastroparesis. It assists in preventing nausea and vomiting related to chemotherapy and surgery. The injection also aids in small bowel intubation in situations where conventional techniques fail to guide a tube through the pylorus. Furthermore, it is utilized to stimulate gastric emptying and facilitate barium transit during radiological procedures.
Who Are The Companies Operating Across The Diabetic Gastroparesis Treatment Market Value Chain?
Major companies operating in the diabetic gastroparesis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Ipca Laboratories Ltd., Abbott Laboratories, AstraZeneca plc, Medtronics plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Janssen Global Services LLC, Boston Scientific Corporation, Fresenius Kabi AG, Bausch Health Companies Inc., Salix Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., Wockhardt Ltd., ANI Pharmaceuticals Inc., Endologic LLC, Vanda Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Theravance Biopharma Inc., Neurogastrx Inc., Evoke Pharma Inc., CinRx Pharma LLC
Get The Full Diabetic Gastroparesis Treatment Market Report:
Which Region Represents The Largest Share Of The Diabetic Gastroparesis Treatment Market?
North America was the largest region in the diabetic gastroparesis treatment market in 2025, and is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic gastroparesis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Diabetic Gastroparesis Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Diabetic Gastroparesis Treatment Market 2026, By The Business Research Company
Diabetic Foot Ulcer Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/diabetic-foot-ulcer-treatment-global-market-report
Gastroparesis Market Report 2026
https://www.thebusinessresearchcompany.com/report/gastroparesis-global-market-report
Gastroparesis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
